Anti-Aging and Life Extension Stocks

by Fred Fuld III

Do you want to live forever? Many billionaires want to, or at least want to support the research into improving and extending the lives of people.

Paul Allen, co-founder of Microsoft (MSFT) created the Allen Institute for Cell Science with $100 million, to develop treatments for diseases related to aging. Unfortunately, he passed away in 2018 from septic shock caused by cancer.

Peter Thiel, co-founder of PayPal (PYPL), has donated money to the SENS Research Foundation, a longevity organization. 

Adam Neumann, former CEO of WeWork, invested in the anti-aging company Life Biosciences.

Google (GOOG) (GOOGL) co-founder Sergey Brin has donated to the Michael J. Fox Foundation and to the Parkinson’s Institute.

There are many companies involved in longevity and life extension through several different approaches, including medical devices, biotechnology, pharmaceuticals, and senior care facilities.

The anti-aging industry is experiencing tremendous growth. The life extension industry is projected by economists to exceed $1 trillion by 2025.

Biotechnology companies are helping people to live longer than ever. This is due in part to efforts in the field of life extension science, which focuses on developing cutting-edge technologies for extending human life. Three technologies of importance in this field are DNA tests to aid in disease prevention, stem cell research, and gene therapy.

Virus

Stem cells allow fetuses to grow complete organs from a single cell. They are used in research to grow transplantable organs. In recent years, scientists have been able to grow replacement body parts and functioning organs. In certain situations, these organs have been successfully transplanted into human patients. Scientists expect that, as this technology continues to advance, the survival rate of patients needing organ transplants will increase dramatically.

One of the challenges in the efforts toward human life extension includes genetic defects that cause fatal diseases. Current research for combating these diseases includes modifying the structure of human DNA through gene therapy. Using gene therapy, scientists can repair damaged DNA by implanting genetic components into human cells.

Some people can inherit a much greater chance of contracting fatal illnesses. With DNA testing, scientists can pinpoint individual genes that cause a high likelihood of developing a specific disease. When locating these harmful genes, fatal diseases can be prevented or treated early enough to prevent death.

Industry experts predict that, at the current rate of advancement, the anti-aging industry may soon surpass that of traditional disease-treating healthcare.

Stocks Targeting Aging

There are several companies working on helping you achieve a greater longevity, which are involved in targeting human aging and degenerative diseases. Here are several that are close to longevity pure plays.

Lineage Cell Therapeutics, Inc. (LCTX) develops and markets therapies for the treatment of various degenerative diseases including age-related macular degeneration, acute spinal cord injuries, non-small cell lung cancer, and various other diseases and disorders. The stock has a market cap of $270 million.

Unity Biotechnology, Inc. (UBX), is a biotechnology company involved in the research and development of therapeutics to extend human life and health. The company’s lead drug candidates include treatments for musculoskeletal/ osteoarthritis disease, moderate-to-severe osteoarthritis of the knee, diabetic macular edema, and ophthalmologic diseases. The stock has a market cap of $47 million.

Cohbar (CWBR) is a clinical stage biotechnology company which concentrates  on the research and development of mitochondria based therapeutics, an emerging class of drugs for the treatment of chronic and age-related diseases.

CohBars therapeutics offer the potential to treat a broad range of diseases, including nonalcoholic steatohepatitis, obesity, fibrotic diseases, cancer, acute respiratory distress syndrome, type 2 diabetes, and cardiovascular and neurodegenerative diseases. This  Menlo Park, California based company was founded in 2007. The stock has a market cap of $16 million.

AgeX Therapeutics, Inc. (AGE) is an Alameda, California based biotechnology company founded in 2017, with a great stock ticker symbol.The company develops and commercializes novel therapeutics targeting human aging.

The company’s two major proprietary technologies can generate pluripotent stem cell-derived young cells of any type for potential application in a range of degenerative diseases of aging with a high unmet medical need. The company has a longevity platform with a goal of unlocking cellular immortality and regenerative capacity to reverse age-related changes in the body. The stock has a market cap of $27 million.

Adicet Bio, Inc. (ACET), has merged with resTORbio, Inc., a Boston, Massachusetts based company founded in 2016, which is involved in developing innovative medicines that target aging to prevent or treat aging-related diseases.

The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. The stock has a market cap of $682 million.

If you are looking for a more diversified way of investing in this arena, there is the  ARK Genomic Revolution ETF (ARKG), which invests in companies involved in genomics.

Please be aware that the above mentioned stocks are extremely low cap companies and should be considered very speculative.

Large Companies in Life Extension

There are some large companies involved in longevity and anti-aging.

One company that fits into this category is Edwards Lifesciences (EW), a California based company involved in the production of products to treat heart disease. This $63.7 billion market cap company trades at 41 times trailing earnings.

Boston Scientific (BSX), a $54.5 billion market cap company, makes and markets an extensive array of cardiology products. The stock has a trailing price-to-earnings ratio of 73.

Vertex Pharmaceuticals Incorporated (VRTX) developer and markets treatments for cystic fibrosis. This $71.7 billion market cap stock trades at 30 times earnings.

Terumo Corporation (TRUMY), based in Japan, makes and markets numerous medical products, primarily for transfusion and cardiothoracic surgery. The $29 billion market cap stock has a PE ratio of 39.

CRISPR

One other related narrow industry in this area is CRISPR. If you are not familiar with what this is, you can check out our CRISPR article.

Just be aware that many of the stocks involved in gene therapy, stem cells, and CRISPR are very low cap companies and therefore, very speculative.

Hopefully, one or more of these stocks will provide you with great returns over a long and healthy life. Who knows? You may not live forever, but at least to the age to 200 or 300.

Disclosure : Author didn’t own any of the above at the time the article was written. No recommendations are expressed or implied.

Longevity Stocks

by Fred Fuld III

We are getting close to a new year, a time when any people establish a resolution to improve their health. Who doesn’t want to live longer and healthier? The wealthy are certainly on board. Paul Allen, co-founder of Microsoft (MSFT) created the Allen Institute for Cell Science to develop treatments for diseases related to aging. Peter Thiel, PayPal (PYPL) co-founder, has donated money to the SENS Research Foundation, a longevity organization. Adam Neumann, the CEO of WeWork, has invested in the anti-aging company Life Biosciences.

There are several companies working on helping you achieve a greater longevity, which are involved in targeting human aging and degenerative diseases. Here are several that are close to longevity pure plays.

Lineage Cell Therapeutics, Inc. (LCTX) develops and markets therapies for the treatment of Various degenerative diseases including age-related macular degeneration, acute spinal cord injuries, non-small cell lung cancer, and various other diseases and disorders. The stock has a market cap of $262 million and has been generating negative earnings. It has $30.7 million in total cash and $3.9 million in long term debt.

Unity Biotechnology, Inc. (UBX), is a biotechnology company involved in the research and development of therapeutics to extend human life and health. The company’s lead drug candidates include treatments for musculoskeletal/ osteoarthritis disease, moderate-to-severe osteoarthritis of the knee, diabetic macular edema, and ophthalmologic diseases. The stock has a market cap of $327 million and has been generating negative earnings. It has $1277 million in total cash and $13 million in long term deferred liabilities.

Cohbar (CWBR) is a clinical stage biotechnology company which concentrates  on the research and development of mitochondria based therapeutics, an emerging class of drugs for the treatment of chronic and age-related diseases. CohBars therapeutics offer the potential to treat a broad range of diseases, including nonalcoholic steatohepatitis, obesity, fibrotic diseases, cancer, acute respiratory distress syndrome, type 2 diabetes, and cardiovascular and neurodegenerative diseases. The company is even in a pre-clinical program for COVID-19 associated ARDS. This  Menlo Park, California based company was founded in 2007. The stock has a market cap of $74 million and has been generating negative earnings. It has $12 million in total cash and long term debt of $3 million.

AgeX Therapeutics, Inc. (AGE) is an Alameda, California based biotechnology company founded in 2017, with a great stock ticker symbol.The company develops and commercializes novel therapeutics targeting human aging. The company’s two major proprietary technologies are PureStem® and induced Tissue Regeneration (iTR™). PureStem® can generate pluripotent stem cell-derived young cells of any type for potential application in a range of degenerative diseases of aging with a high unmet medical need. iTR™ is the company’s longevity platform with a goal of unlocking cellular immortality and regenerative capacity to reverse age-related changes in the body. The stock has a market cap of $64 million and has been generating negative earnings. It has $2 million in total cash and $1.5 million in long term debt.

Adicet Bio, Inc. (ACET), has merged with resTORbio, Inc., a Boston, Massachusetts based company founded in 2016, which is involved in developing innovative medicines that target aging to prevent or treat aging-related diseases. The company’s lead clinical program is selectively targeting TORC1, an evolutionarily conserved pathway that contributes to the age-related decline in function of multiple organ systems, including neurologic function. Adicet Bio develops allogeneic gamma delta T cell therapies for cancer and other diseases. The stock has a market cap of $247 million and has been generating negative earnings. It has $5.49 cash per share and no long term debt.

If you are looking for a more diversified way of investing in this arena, there is the Global X Longevity Thematic ETF (LNGR), an exchange traded fund with investments in companies that facilitate the trend of longer average life spans and the aging of the population.

There is also the ARK Genomic Revolution ETF (ARKG), which invests in companies involved in genomics.

Please be aware that the mentioned stocks are extremely low cap stocks and should be considered very speculative.

Disclosure: Author didn’t own any of the above at the time the article was written.

 

The Top Three Age Reversal and Age Extension Stocks

by Fred Fuld III

The baby boomers are getting older, and as they age, they become more concerned about their health, living as long as they can, and living as healthy as they can. The boomers get concerned about age related illnesses and diseases that can affect them.

Fortunately, there are a few companies involved in targeting human aging and degenerative diseases. There are many companies involved in developing treatments and cures for many diseases, such as cancer, and may have a small part of their business involved in age reversal. But there aren’t many companies involved age extension as a pure play. Here are a few longevity stocks worth doing further research on.

Cohbar (CWBR) is a clinical stage biotechnology company which concentrates  on the research and development of mitochondria based therapeutics, an emerging class of drugs for the treatment of chronic and age-related diseases. CohBars therapeutics offer the potential to treat a broad range of diseases, including nonalcoholic steatohepatitis, obesity, fibrotic diseases, cancer, acute respiratory distress syndrome, type 2 diabetes, and cardiovascular and neurodegenerative diseases. The company is even in a pre-clinical program for COVID-19 associated ARDS. This  Menlo Park, California based company was founded in 2007. The stock has a market cap of $97 million and has been generating negative earnings. It has $12.5 million in total cash and long term debt of $3.4 million.

AgeX Therapeutics, Inc. (AGE) is an Alameda, California based biotechnology company founded in 2017, with a great stock ticker symbol.The company develops and commercializes novel therapeutics targeting human aging. The company’s two major proprietary technologies are PureStem® and induced Tissue Regeneration (iTR™). PureStem® can generate pluripotent stem cell-derived young cells of any type for potential application in a range of degenerative diseases of aging with a high unmet medical need. iTR™ is the company’s longevity platform with a goal of unlocking cellular immortality and regenerative capacity to reverse age-related changes in the body. The stock has a market cap of $32 million and has been generating negative earnings. It has $2.3 million in total cash and $1.5 million in long term debt.

resTORbio, Inc. (TORC) is a Boston, Massachusetts based company founded in 2016, which is involved in developing innovative medicines that target the biology of aging to prevent or treat aging-related diseases. The company’s lead clinical program is selectively targeting TORC1, an evolutionarily conserved pathway that contributes to the age-related decline in function of multiple organ systems, including neurologic function. Inhibition of TORC1 has the potential to improve the function of aging organ systems and address multiple aging related diseases. The stock has a market cap of $77 million and has been generating negative earnings. It has total cash of $91 million and virtually no long term debt.

Please be aware that these are extremely low cap stocks and should be considered very speculative.

Disclosure: Author owns CWBR.

How to Live Forever & the Stocks that will Benefit

Do you want to live forever? Many billionaires want to, or at least want to support the research into improving and extending the lives of people. Paul Allen, co-founder of Microsoft (MSFT) created the Allen Institute for Cell Science with $100 million, to develop treatments for diseases related to aging. Unfortunately, he passed away last year from septic shock caused by cancer.

Adam Neumann, the CEO of WeWork, has invested in the anti-aging company Life Biosciences. Peter Thiel, co-founder of PayPal (PYPL), has donated money to the SENS Research Foundation, a longevity organization. Google (GOOG) (GOOGL) co-founder Sergey Brin has donated to the Michael J. Fox Foundation and to the Parkinson’s Institute.

There are many companies involved in longevity through several different approaches, including medical devices, biotechnology, pharmaceuticals, and senior care facilities.

One company that fits into this category is Edwards Lifesciences (EW), a California based company involved in the production of products to treat heart disease. This $44.7 billion market cap company trades at 44 times trailing earnings and 35 times forward earnings. Earnings for the latest reported year were up 23.7% over the previous year.

Boston Scientific (BSX), a $60 billion market cap company, makes and markets an extensive array of cardiology products. The sock has a trailing price-to-earnings ratio of 43 and a forward PE ratio of 24.

Vertex Pharmaceuticals Incorporated (VRTX) developer and markets treatments for cystic fibrosis. The stock trades at 21 times earnings.

Terumo Corporation (TRUMY), based in Japan, makes and markets numerous medical products, primarily for transfusion and cardiothoracic surgery. The stock has a PE ratio of 13.

All of the above, plus many other longevity related stocks make up the portfolio of the Global X Longevity Thematic ETF (LNGR), which has a portfolio of anti-aging stocks. It pays a small yield of 0.85%.

Hopefully some of these stocks will make your portfolio last a long time.

Disclosure: Author didn’t own any of the above at the time the article was written.

 

Drink Booze, Live Longer, Make Money with Wine & Alcohol Stocks

Here it is. The news you’ve been waiting for. Wondering if having that glass of wine or liquor after work or with dinner is healthy for you? Fortunately for you, scientists at UC Irvine have found that drinking alcohol is better than exercise for living a long life into the 90s.

Over 1,600 participants were involved in the study, with ages ranging from 90 to 99. Researchers found that those who drank two glasses of alcohol or wine a day reduced the chance of an early death by 18%.

So what’s an investor to do in order to have a healthy and long-lived portfolio? Many investors look to stocks of companies involve in the production and sale of alcoholic beverages.

Constellation Brands Inc (STZ), founded in 1945, is a California based company with such brands as Robert Mondavi, Clos du Bois, Ravenswood, Black Velvet, and Canadian Whiskey. The stock trades at 22.9 times forward earnings and pays a dividend of slightly less than one percent.

Diageo (DEO), founded in 1997, is based in the UK. It’s brands include Blossom Hill, Sterling Vineyards, Beaulieu Vineyard, Navarro Correas, Acacia Vineyard, Rosenblum Cellars, Piat d’Or, Chalone Vineyard, and Santa Rita. The stock has a forward price to earnings ratio of 18.9 and offers a generous yield of 2.6%.

For a list of other wine and liquor stocks, go  HERE.

By the way, if you are in your nineties and want to participate in the study,  contact 949.768.3635 or study90@uci.edu for more information.